Skip to main content
. 2022 Jun 6;5(6):e2215589. doi: 10.1001/jamanetworkopen.2022.15589

Figure 2. Time to Second Progression (PFS2) in Patients With or Without Driver Variations Who Progressed After Definitive Chemoradiation and Consolidative Durvalumab.

Figure 2.

A, Median time after the first episode of disease progression (PFS2) was 13.7 months for patients with non–KRAS driver variations vs 4.4 months for all other patients (log-rank P = .002). B, Median PFS2 time was 13.7 months for patients with non–KRAS driver variations, 4.0 months for patients with KRAS driver variations, and 4.5 months for patients without driver variations (log-rank P = .007).